All In Biotech

Drug Trial Radar · NCT01051661

Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age

A Study to Evaluate the Safety and Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children Aged 6 Months to Less Than 10 Years of Age

Last checked: Nov 20, 2026Latest source record: Feb 26, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 6,154 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,154

Actual

Start

Feb 12, 2010

Primary completion

Aug 31, 2011

Study completion Sep 9, 2011

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jan 18, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 6 months, up to 9 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterize the safety and efficacy of GSK Biologicals' H1N1 flu candidate vaccines GSK2340274A and GSK2340273A in children 6 months to less than 10 years of age.

Conditions

  • Influenza

Interventions

  • GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)Biological

    Intramuscular injection, one or two doses

  • GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations)Biological

    Intramuscular injection, two doses

  • PlaceboBiological

    Intramuscular injection, one dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects Reporting at Least One A/California Influenza EventTime frame: From 14 days after first vaccination until study conclusion on Day 385

Locations

17 sites in 8 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Kippa-Ring, Queensland, Australia

  • GSK Investigational Site

    Carlton, Victoria, Australia

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    Florianópolis, Santa Catarina, Brazil

  • GSK Investigational Site

    Cali, Colombia

  • GSK Investigational Site

    San José, Costa Rica

  • GSK Investigational Site

    Durango, Mexico

  • GSK Investigational Site

    Mexico City, Mexico

  • GSK Investigational Site

    Monterrey, Mexico

  • GSK Investigational Site

    Cuernavaca, Morelos, Mexico

  • GSK Investigational Site

    City of Muntinlupa, Philippines

  • GSK Investigational Site

    Dasmariñas, Cavite, Philippines

  • GSK Investigational Site

    Sampaloc, Manila, Philippines

  • GSK Investigational Site

    Singapore, Singapore

  • GSK Investigational Site

    Bangkok, Thailand

  • GSK Investigational Site

    Khon Kaen, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.